CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,949 | -32.4% | 143,463 | -16.7% | 0.00% | -50.0% |
| Q2 2023 | $5,841 | +48.9% | 172,134 | +57.9% | 0.00% | +100.0% |
| Q1 2023 | $3,922 | -24.4% | 109,024 | -6.4% | 0.00% | 0.0% |
| Q4 2022 | $5,191 | -99.9% | 116,471 | -19.4% | 0.00% | -50.0% |
| Q3 2022 | $4,064,000 | +55.2% | 144,587 | +48.9% | 0.00% | +100.0% |
| Q2 2022 | $2,618,000 | -62.8% | 97,087 | -53.0% | 0.00% | -66.7% |
| Q1 2022 | $7,041,000 | -34.9% | 206,700 | -26.2% | 0.01% | +200.0% |
| Q4 2021 | $10,816,000 | +403.8% | 279,904 | +603.8% | 0.00% | +100.0% |
| Q3 2021 | $2,147,000 | +194.1% | 39,768 | +82.2% | 0.00% | – |
| Q2 2021 | $730,000 | -36.0% | 21,825 | -60.5% | 0.00% | -100.0% |
| Q1 2021 | $1,140,000 | +12566.7% | 55,299 | +10959.8% | 0.00% | – |
| Q4 2020 | $9,000 | -30.8% | 500 | -42.3% | 0.00% | – |
| Q3 2020 | $13,000 | – | 866 | +43200.0% | 0.00% | – |
| Q2 2020 | $0 | – | 2 | -92.3% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 26 | -99.3% | 0.00% | – |
| Q2 2019 | $10,000 | -77.8% | 3,926 | -57.0% | 0.00% | – |
| Q1 2019 | $45,000 | – | 9,126 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |